Here’s what’s happening today in the world of CBD research, products and announcements:
“One reason there has been so little in the United States is precisely because cannabis is listed on Schedule I, a designation that creates significant barriers to pursuing federally funded research into potential medical benefits. This was recently backed up by U.S. Surgeon General Jerome Adams, who said, “one of the concerns that I have with marijuana is the difficulty that folks have to do research on it, because of the scheduling system.” Interestingly, it is easier to obtain funding and approval for cocaine research, which is a Schedule II drug.”
The U.S. hemp industry is expecting business to expand and investors to beckon after Congress on Wednesday passed farm legislation that included a provision to legalize and regulate the plant under the Department of Agriculture.
“This is a monumental bill for hemp farming,” said Lauren Stansbury, communications director for Vote Hemp, a national lobbying organization for hemp producers.
The bill, awaiting President Trump’s signature, opens the door to state-by-state regulation, removes hemp, which is part of the cannabis plant family, from the federal enforcement of outlaw drugs and gives hemp farmers access to banking, crop insurance and federal grants, experts said.
A higher percentage of California marijuana products are passing strict safety tests, but the sudden closing of a lab that state authorities found wasn’t correctly checking for pesticides has raised new questions about the system intended to protect the purity and potency of legal cannabis.
New Zealand will hold a referendum on whether to legalise cannabis for recreational use at the general election in 2020, a week after legalising the use of cannabis for medicinal purposes.
The governing Labour party promised the Green party they would hold a national referendum on legalising the drug, as part of the confidence and supply agreement between the two.
Cannabis is widely consumed in New Zealand with police largely turning a blind eye to small-scale, personal use.